A new study from the Irvine and Wittrup labs, published in Nature Immunology, describes a novel immunotherapy approach that delivers and retains cytokines directly in tumors and nearby lymph nodes via a combination of locally administered IL-12 and IL-15, both engineered to target the CD45 receptor.
Unlike other efforts, this approach localizes the effects of cytokines, ensuring that the drugs stay inside the tumor and neighboring lymph nodes to prevent leakage and the severe systemic side effects that accompany it.